Watch Ticker

Annexon, Inc. Common Stock

Go to Annexon, Inc. Common Stock Website

$2.48

-0.05 (-1.98%)

Live

Previous Close

$2.53

Day Range

$2.435 - $2.56

Previous Day Range

$2.435 - $2.62

Market Cap

$268.8 million USD

Day Vol.

631148

Previous Day Vol.

1.0 million

Currency

USD

Primary Exchange

Nasdaq

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Annexon, Inc. - Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Annexon completed enrollment for its Phase 3 ARCHER II trial of vonaprument, a potential treatment for dry age-related macular degeneration with geographic atrophy. The trial aims to demonstrate vision preservation and is expected to report topline data in the second half of 2026.

Related tickers: ANNX.

Read Full Article

Delveinsight - Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight

The Huntington's disease treatment market is poised for significant growth, driven by rising prevalence rates, advancements in gene-targeting and disease-modifying therapies, and a robust clinical pipeline addressing critical unmet needs.

Related tickers: ANNX, ALNY.

Read Full Article

Trending Tickers

Please sign in to view